rupatadine has been researched along with montelukast in 2 studies
| Studies (rupatadine) | Trials (rupatadine) | Recent Studies (post-2010) (rupatadine) | Studies (montelukast) | Trials (montelukast) | Recent Studies (post-2010) (montelukast) |
|---|---|---|---|---|---|
| 116 | 43 | 62 | 1,965 | 598 | 777 |
| Protein | Taxonomy | rupatadine (IC50) | montelukast (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 3.197 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 4.702 | |
| Beta-2 adrenergic receptor | Homo sapiens (human) | 3.488 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.689 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 3.919 | |
| Adenosine receptor A3 | Homo sapiens (human) | 0.434 | |
| Cytochrome P450 2C8 | Homo sapiens (human) | 0.7 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 8.045 | |
| Beta-3 adrenergic receptor | Homo sapiens (human) | 4.3 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.434 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 5.279 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 6.626 | |
| Substance-K receptor | Homo sapiens (human) | 3.822 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.689 | |
| Thromboxane-A synthase | Homo sapiens (human) | 1.525 | |
| D(3) dopamine receptor | Homo sapiens (human) | 7.747 | |
| Delta-type opioid receptor | Homo sapiens (human) | 4.795 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 6.256 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.434 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.601 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.856 | |
| Leukotriene C4 synthase | Homo sapiens (human) | 5 | |
| Cysteinyl leukotriene receptor 1 | Homo sapiens (human) | 0.0015 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Didiodato, G; Gerard, L; Hopkins, S; Kotchetkov, R; McLean, J; Nay, D | 1 |
| El-Ghany, SEA; Hegazy, SK; Kotkata, FAE; Mostafa, TM | 1 |
1 trial(s) available for rupatadine and montelukast
| Article | Year |
|---|---|
Comparative study evaluating antihistamine versus leukotriene receptor antagonist as adjuvant therapy for rheumatoid arthritis.
Topics: Acetates; Adult; Arthritis, Rheumatoid; Body Mass Index; C-Reactive Protein; Clusterin; Cyclopropanes; Cyproheptadine; Double-Blind Method; Drug Therapy, Combination; E-Selectin; Egypt; Female; Histamine Antagonists; Humans; Immunosuppressive Agents; Interleukins; Leukotriene Antagonists; Male; Methotrexate; Middle Aged; Quinolines; Sulfides | 2021 |
1 other study(ies) available for rupatadine and montelukast
| Article | Year |
|---|---|
Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications.
Topics: Acetaminophen; Acetates; Adult; Aged; Aged, 80 and over; Cyclopropanes; Cyproheptadine; Diphenhydramine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lymphoproliferative Disorders; Male; Middle Aged; Premedication; Quinolines; Rituximab; Standard of Care; Sulfides; Treatment Outcome | 2020 |